Abstract
Objective: To provide an overview of the status of applying genome editing, particularly CRISPR/Cas9, in the management of cancer. Method: Several search tools were consulted in the preparation of this manuscript to obtain peer-reviewed articles using the given evaluation and selection criteria. Main points: CRISPR/Cas9 and its associated variants stood out as the technology of choice for manipulating cancer cells and managing the disease. This genome-editing technology can positively contribute to the elucidation of the roles of cancer genes, establish animal models to study the disease, and therapeutically empower the development of next-generation immunotherapies. Conclusions: The manipulation of the human genome using CRISPR/Cas9 to treat cancer has only recently begun. Several clinical trials are ongoing, and the results are eagerly awaited. In the meantime, improvements and advancements in genome editing are being developed at a rapid pace to take advantage of this evolving technology.
Publisher
Al-Rafidain University College